Tafamidis

echo.png
Jul 11, 2023
Amyloidosis now a hot topic in cardiac imaging due to new drug treatment
July 11, 2023 | Cardiovascular Business For years, cardiac amyloidosis was a rare and often fatal disease that had no treatment, so it was not front and center in…
Read more
Jan 29, 2023
Long-term survival in people with transthyretin amyloid cardiomyopathy who took tafamidis: a plain language summary
What is this plain language summary about? This summary presents the results from an ongoing, long-term extension studyexternal link, opens in a new tab that…
Read more
pfizer_logo.jpg
U.S. FDA Approves VYNDAQEL® and VYNDAMAX™ for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved both VYNDAQEL(R) (tafamidis meglumine) and VYNDAMAX(tm) (tafamidis) for…
Read more
Martha-Gulati.jpg
ESC: Tafamidis Cuts Deaths, Admissions in TTR Cardiac Amyloidosis
Treatment with the investigational drug tafamidis was associated with a reduction in all-cause mortality and cardiovascular hospitalizations in patients with…
Read more
pfizer_logo.jpg
US FDA Accepts Regulatory Submissions for Review of Tafamidis to Treat Transthyretin Amyloid Cardiomyopathy
Pfizer Inc. announced today that the US Food and Drug Administration (FDA) accepted for filing the company's New Drug Applications (NDAs) for tafamidis for the…
Read more
Subscribe to